Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

Nature Biotechnology

Volumn 29, Issue 11, 2011, Pages 1039-1045

  Anastassiadis, Theonie ^a   Deacon, Sean W ^b   Devarajan, Karthik ^a   Ma, Haiching ^b   Peterson, Jeffrey R ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b REACTION BIOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATP-BINDING SITE; CELLULAR SIGNALING; DRUG DEVELOPMENT; EVOLUTIONARY CONSERVATIONS; FUNCTIONAL ASSAYS; INTERPRETATION OF EXPERIMENTS; KINASE FUNCTION; KINASE INHIBITORS; PROTEIN KINASE; PROTEIN KINASE INHIBITORS; RECOMBINANT PROTEIN; SMALL MOLECULES; THERAPEUTIC AGENTS; WIDE SPECTRUM;

ASSAYS; CATALYST ACTIVITY; EXPERIMENTS; PROTEINS;

ENZYMES;

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 BENZYLOXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 ETHYL 2 (4 METHOXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ATM KINASE INHIBITOR; BPIQ 1; DASATINIB; DMBI; GEFITINIB; GTP 14564; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PD 174265; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B INHIBITOR; SC 68376; STAUROSPORINE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME ASSAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

CATALYSIS; DRUG DESIGN; ENZYME STABILITY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 80755125565     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2017     Document Type: Article

References (36)

1. Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005). (Pubitemid 41094421)
2. Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
3. Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523-20528 (2007).
4. Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315 (2007).
5. Davies, S.P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105 (2000).
6. Bain, J., McLauchlan, H., Elliott, M. & Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204 (2003). (Pubitemid 36458094)
7. Ma, H., Deacon, S. & Horiuchi, K. The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin. Drug Discov. 3, 607-621 (2008). (Pubitemid 351890673)
8. Smyth, L.A. & Collins, I. Measuring and interpreting the selectivity of protein kinase inhibitors. J. Chem. Biol. 2, 131-151 (2009).
9. Goldstein, D.M., Gray, N.S. & Zarrinkar, P.P. High-throughput kinase profiling as a platform for drug discovery. Nat. Rev. Drug Discov. 7, 391-397 (2008). (Pubitemid 351619111)
10. Miduturu, C.V. et al. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem. Biol. 18, 868-879 (2011).
11. Daub, H., Specht, K. & Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3, 1001-1010 (2004). (Pubitemid 39642363)
12. Morphy, R., Kay, C. & Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today 9, 641-651 (2004). (Pubitemid 38981718)
13. Metz, J.T. et al. Navigating the kinome. Nat. Chem. Biol. 7, 200-202 (2011).
14. Dodson, C.A. et al. Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. Biochem. J. 427, 19-28 (2010).
15. Graczyk, P.P. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. J. Med. Chem. 50, 5773-5779 (2007). (Pubitemid 350106032)
16. Bamborough, P., Drewry, D., Harper, G., Smith, G.K. & Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 51, 7898-7914 (2008).
17. Faivre, S., Djelloul, S. & Raymond, E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol. 33, 407-420 (2006). (Pubitemid 44142738)
18. Morphy, R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem. 53, 1413-1437 (2010).
19. Knight, Z.A., Lin, H. & Shokat, K.M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130-137 (2010).
20. Cockerill, S. et al. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFR and c-erbB-2. Bioorg. Med. Chem. Lett. 11, 1401-1405 (2001). (Pubitemid 32510830)
21. Lapenna, S. & Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547-566 (2009).
22. Zhang, Q. et al. Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. J. Am. Chem. Soc. 128, 2182-2183 (2006).
23. Lee, J.C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746 (1994).
24. Cuny, G.D. et al. Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. Bioorg. Med. Chem. Lett. 20, 3491-3494 (2010).
25. Huertas, D. et al. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene published online, doi:10.1038/onc.2011.335 (1 August 2011).
26. Patnaik, D. et al. Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay. J. Biomol. Screen. 13, 1025-1034 (2008).
27. Mencher, S.K. & Wang, L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin. Pharmacol. 5, 3 (2005).
28. Liao, J.K., Seto, M. & Noma, K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol. 50, 17-24 (2007). (Pubitemid 47220442)
29. Yarrow, J.C., Totsukawa, G., Charras, G.T. & Mitchison, T.J. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem. Biol. 12, 385-395 (2005). (Pubitemid 40406285)
30. Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 12, 621-637 (2005). (Pubitemid 43142039)
31. Fedorov, O., Muller, S. & Knapp, S. The (un)targeted cancer kinome. Nat. Chem. Biol. 6, 166-169 (2010).
32. Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275-282 (2002). (Pubitemid 34606870)
33. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002). (Pubitemid 35425239)
34. Yee, T.W. & Hastie, T.J. Reduced-rank vector generalized linear models. Stat. Modelling 3, 15-41 (2003).
35. van der Loo, M.P.J. Distribution-based outlier detection for univariate data. Discussion paper 10003 (Statistics Netherlands, The Hague, 2010).
36. Cheng, Y. & Prusoff, W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108 (1973).